MyFinsight
Home
Blog
About
Contact
Download
Download image
VOXZOGO
$219,880K
(2.87%↑ Y/Y)
VIMIZIM
$210,204K
(11.61%↑ Y/Y)
NAGLAZYME
$130,074K
(13.81%↑ Y/Y)
PALYNZIQ
$89,558K
(-3.98%↓ Y/Y)
BRINEURA
$47,104K
(16.70%↑ Y/Y)
ALDURAZYME
$36,742K
(-24.98%↓ Y/Y)
KUVAN
$23,880K
(-5.00%↓ Y/Y)
ROCTAVIAN
$2,636K
(-74.92%↓ Y/Y)
Product
$760,078K
(3.46%↑ Y/Y)
Royalty And Other
$6,130K
(-41.62%↓ Y/Y)
Total revenues
$766,208K
(2.83%↑ Y/Y)
Income from operations
$129,640K
(-42.10%↓ Y/Y)
Interest income
$22,560K
(18.66%↑ Y/Y)
Total operating
expenses
$636,568K
(22.12%↑ Y/Y)
Other income
(expense), net
$3,961K
(302.71%↑ Y/Y)
Income before income
taxes
$141,203K
(-40.69%↓ Y/Y)
Interest expense
$14,958K
(422.46%↑ Y/Y)
Selling, general and
administrative
$258,290K
(25.31%↑ Y/Y)
Cost of sales
$194,999K
(28.66%↑ Y/Y)
Research and development
$178,796K
(12.64%↑ Y/Y)
Intangible asset
amortization
$4,483K
(-7.51%↓ Y/Y)
Net income
$105,527K
(-43.17%↓ Y/Y)
Provision for income taxes
$35,676K
(-31.92%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)